Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Josep Maria del Campo,Ursula A. Matulonis,Susanne Malander,Diane Provencher,Sven Mahner,P. Follana,Justin Waters,Jonathan S. Berek,Kathrine Woie,Amit M. Oza,Ulrich Canzler,Marta Gil-Martin,Anne Lesoin,Bradley J. Monk,Bente Lund,Lucy Gilbert,Robert M. Wenham,Benedict B. Benigno,Sujata Arora,Sebastien Hazard,Mansoor Raza Mirza

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

2019

PURPOSEIn the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in...

Keywords:

Recurrent Ovarian Cancer
Pathology
Oncology
Internal medicine
Medicine
Maintenance therapy
Chemotherapy
Cohort
Placebo
Cancer
Physical therapy
Hazard ratio
BRCA mutation
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations